Overview
IOVA market data
Price History
IOVA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.09 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.85 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -89.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.76 – $6.92 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3B · P/B 1.55 · P/S 9.16.
Company News
Iovance Biotherapeutics Stock Soars After the Company Posts Strong Q2 Earnings. Is It Heading Even Higher?The Motley Fool · Aug 10, 2026, 8:15 PM
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $13Benzinga · Aug 7, 2026, 6:37 PM
Citizens Maintains Market Outperform on Iovance Biotherapeutics, Raises Price Target to $8Benzinga · Aug 7, 2026, 3:01 PM
8-K filing — IOVANCE BIOTHERAPEUTICS, INC. (IOVA)SEC EDGAR · Aug 6, 2026, 9:30 PM
Iovance (IOVA) Stock Soars After Better-Than-Expected Q2 ResultsBenzinga · Aug 6, 2026, 6:06 PM
Iovance Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 6, 2026, 3:34 PM
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On ThursdayBenzinga · Aug 6, 2026, 2:01 PM
Iovance Biotherapeutics Affirms FY2026 Sales Guidance of $350.000M-$370.000M vs $362.083M EstBenzinga · Aug 6, 2026, 11:11 AM
Iovance Biotherapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate, Sales $99.313M Beat $87.832M EstimateBenzinga · Aug 6, 2026, 11:05 AM
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)Globenewswire Inc · Jul 17, 2026, 10:31 PM